Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics is conducting a Phase 1 study titled ‘Evaluation of Miricorilant on Liver Fat in Patients With MASLD.’ The study aims to assess the effect of Miricorilant on hepatic lipids in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH). This research is significant as it targets a condition linked to metabolic disorders, offering potential therapeutic advancements.
The intervention being tested is Miricorilant, an experimental drug administered orally at a dose of 100 mg daily. Its purpose is to reduce liver fat in patients with MASH, potentially offering a new treatment avenue for this condition.
This open-label study involves a single group of approximately 8 patients, who will receive the treatment for four weeks. There is no masking involved, and the primary purpose is treatment-focused, aiming to gather initial data on the drug’s efficacy and safety.
The study began on August 1, 2025, with an update on August 11, 2025. These dates are crucial as they mark the study’s commencement and the latest information available, indicating that the study is actively recruiting participants.
The market implications of this study are noteworthy. If successful, Miricorilant could enhance Corcept Therapeutics’ portfolio, potentially boosting its stock performance. Investor sentiment may improve with positive interim results, especially given the competitive landscape in liver disease treatments.
The study is ongoing, with further details accessible on the ClinicalTrials portal.